Filing Details

Accession Number:
0000899243-22-002911
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-21 18:22:38
Reporting Period:
2021-01-19
Accepted Time:
2022-01-21 18:22:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1739410 Rallybio Corp RLYB Pharmaceutical Preparations (2834) 851083789
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1872879 M Jeffrey Fryer C/O Rallybio Corporation
234 Church Street, Suite 1020
New Haven CT 06510
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-19 1,400 $8.70 44,048 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 272,609 Indirect See Footnote
Common Stock 201,934 Indirect See Footnote
Common Stock 201,934 Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. Shares of common stock are held in a Roth IRA.
  3. Shares of common stock are held in a revocable trust for which Mr. Fryer is the grantor.
  4. Shares of common stock are held in an irrevocable trust for the benefit of one of Mr. Fryer's children. Mr. Fryer disclaims beneficial ownership of such shares.
  5. Shares of common stock are held in an irrevocable trust for the benefit of one of Mr. Fryer's children. Mr. Fryer disclaims beneficial ownership of such shares.